Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Google Halts UK YouTube TV Measurement Service After Legal Action 
Trump Family Files $10 Billion Lawsuit Over IRS Tax Disclosure 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
New York Judge Orders Redrawing of GOP-Held Congressional District 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
China Overturns Death Sentence of Canadian Robert Schellenberg, Signaling Thaw in Canada-China Relations 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Federal Judge Restores Funding for Gateway Rail Tunnel Project 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Chemours, Dupont De Nemours, and Corteva have announced a $110 million settlement with the U.S. state of Ohio to resolve claims linked to toxic "forever chemicals." This agreement aims to address concerns surrounding per- and polyfluoroalkyl substances (PFAS).
Nasdaq reported that the chemical has been associated with various health risks. The settlement covers costs related to the release of PFAS from the companies' facilities, including the Washington Works site situated along the Ohio-West Virginia border, as per Reuters.
Responsibility Distribution for Settlement Costs
According to the agreement, Chemours, a spin-off of DuPont, will bear 50% of the settlement costs, while DuPont will contribute approximately $39 million. Corteva, on the other hand, is expected to cover the remaining expenses. The resolution brings an end to Ohio's claims concerning the release of PFAS, affording the state an opportunity to address this issue comprehensively.
The resolution of the Ohio settlement emphasizes the importance of addressing the wide-reaching implications of PFAS contamination.
Notably, the settlement between the companies and Ohio has triggered a contingency provision outlined in Delaware's 2021 PFAS settlement with the same entities.
This provision requires an additional payment of $25 million to the state of Delaware and the original $50 million settlement if a similar agreement is reached within eight years with another state, amounting to over $50 million. This provision underlines the accountability held by chemical manufacturers in addressing the concerns associated with PFAS contamination.
Legal Battles Surrounding PFAS
Chemical manufacturers have faced numerous lawsuits in recent years regarding alleged PFAS contamination. In a significant ruling, a U.S. appeals court rejected a lower court's decision that would have allowed approximately 11.8 million Ohio residents to sue 10 PFAS manufacturers as a collective group. The legal landscape demonstrates the complexity surrounding PFAS-related claims and the efforts to hold responsible parties accountable for their actions.
In June, 3M agreed to a $10.3 billion settlement to address hundreds of claims alleging the company had contaminated public drinking water with PFAS. Similarly, Chemours, DuPont, and Corteva reached a separate settlement with U.S. water providers, amounting to $1.19 billion.
These settlements underscore the growing recognition within the industry regarding the need to address PFAS-related concerns and the responsibility manufacturers bear in ensuring the safety of their products and practices.
Photo: DuPont Newsroom
